ASN: Hypertension Most Common Cardiovascular Comorbidity Seen With Dialysis
By Lori Solomon HealthDay Reporter
WEDNESDAY, Oct. 30, 2024 -- Hypertension is the most common cardiovascular disease (CVD) comorbidity seen among dialysis patients globally, according to a study presented at Kidney Week, the annual meeting of the American Society of Nephrology, held from Oct. 23 to 27 in San Diego.
Belen Alejos, Ph.D., from Fresenius Medical Care in Bad Homburg, Germany, and colleagues analyzed CVD prevalence among 543,169 dialysis patients treated in 40 countries across six continents. The analysis included data from the first version of a global dialysis database (Apollo Dial DB; January 2018 to March 2021).
The researchers found that 79 percent of included patients reported at least one CVD condition, including most commonly hypertension (73.6 percent). There were some differences observed in the prevalence of CVD conditions by age and sex. For example, atherosclerotic heart disease affected 19.0 percent, with prevalence increasing with age (9.9 percent in ages 18 to 44 years to 24.1 percent in ages 75 years and older). Atherosclerotic heart disease was also more common in men (20.3 percent) than women (17.2 percent). A similar trend was seen for congestive heart failure, which affected 17.5 percent overall but increased with age. Other lower prevalence conditions, such as peripheral vascular disease (11.5 percent), cardiomyopathy (7.3 percent), and cardiac dysrhythmias (7.1 percent), were all more prevalent in older age groups and in men.
"Hypertension is the most common CVD comorbidity among dialysis patients globally, followed by atherosclerotic heart disease and congestive heart failure," the authors write. "Future analyses are needed to explore differences by world region, which could inform region-specific management strategies."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted October 2024
Read this next
Hypertensive Disorders of Pregnancy Adversely Affect Preemie Neurodevelopment
THURSDAY, May 1, 2025 -- Maternal hypertensive disorders of pregnancy (HDP) are associated with adverse cognitive and language development in preterm infants at 2 years' corrected...
Lorundrostat Beneficial for BP Reduction in Uncontrolled Hypertension
WEDNESDAY, April 30, 2025 -- For patients with uncontrolled and treatment-resistant hypertension, lorundrostat is associated with greater reductions in blood pressure than...
Intensive BP Reduction Effective for Lowering All-Cause Dementia Risk
TUESDAY, April 29, 2025 -- An intensive blood pressure (BP) reduction intervention is effective for lowering the risk for all-cause dementia among individuals aged 40 years and...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.